Medscape Hematology-Oncology Headlines 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Will AI Clinical Notes Benefit Your Practice? Will AI Clinical Notes Benefit Your Practice?
Artificial intelligence expert Arturo Loaiza-Bonilla, MD, discusses the benefits of AI-based clinical notes.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Oncologists Voice Ethical Concerns Over AI in Cancer Care Oncologists Voice Ethical Concerns Over AI in Cancer Care
A survey of oncologists highlighted ethical issues over the use of AI in cancer care and revealed some contradictory views about how best to integrate these tools.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Clinical Summary Source Type: news
No Routine Cancer Screening Option? New MCED Tests May Help No Routine Cancer Screening Option? New MCED Tests May Help
Early data suggest that several new multicancer early detection tests can identify a range of cancers that lack routine screening options.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Further Support for CRC Screening to Start at Age 45 Further Support for CRC Screening to Start at Age 45
Adenoma detection rates were shown to be comparable between 45-49-year-olds and 50-54-year-olds.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2024 Category: Cancer & Oncology Tags: Gastroenterology Clinical Summary Source Type: news
Ovarian Cancer: Another Promising Target for Liquid Biopsy Ovarian Cancer: Another Promising Target for Liquid Biopsy
A blood test to screen for ovarian cancer is one of many new liquid biopsy assays being evaluated to screen for cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New Findings: More Cancer Diagnoses, Fewer Cancer Deaths New Findings: More Cancer Diagnoses, Fewer Cancer Deaths
Dr Maurie Markman discusses the American Cancer Society Annual Report.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
More Adults Are Participating in Cancer Clinical Trials More Adults Are Participating in Cancer Clinical Trials
New estimates suggest that more adults with cancer are participating in cancer trial research, especially at National Cancer Institute –designated centers, but overall enrollment rates remain low.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Clinical Summary Source Type: news
ImPrint Identifies Treatment for Patients With Breast Cancer ImPrint Identifies Treatment for Patients With Breast Cancer
Data from the ongoing phase 2 trial show that clinicians can use ImPrint, an immune-related biomarker, to identify breast cancer patients who are likely to respond to neoadjuvant immunotherapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Combo Therapy Prolongs Survival in Gastric Cancer Patients Combo Therapy Prolongs Survival in Gastric Cancer Patients
The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 10, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Intermediate Endpoints Predict Breast Cancer Survival Intermediate Endpoints Predict Breast Cancer Survival
Data suggest that intermediate clinical endpoints can serve as surrogate endpoints for overall survival in patients with early-stage breast cancer receiving adjuvant therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 10, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Should High-Risk Asymptomatic Bone Mets Be Irradiated? Should High-Risk Asymptomatic Bone Mets Be Irradiated?
Dr Maurie Markman discusses results from a study of prophylactic radiation for high-risk asymptomatic bone metastases.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 9, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
DIY: Seborrheic Keratosis Eradication DIY: Seborrheic Keratosis Eradication
The national cost of SK removal for cosmetic reasons is staggering, but does it have to be this way?Medscape Internal Medicine (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 9, 2024 Category: Cancer & Oncology Tags: Internal Medicine Source Type: news
FDA Expands Enhertu Indication to HER2-Positive Solid Tumors FDA Expands Enhertu Indication to HER2-Positive Solid Tumors
The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 9, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Abecma Approved for Earlier Lines in R/R Multiple Myeloma Abecma Approved for Earlier Lines in R/R Multiple Myeloma
The drug manufacturers report a complete response rate of 39% with idecabtagene vicleucel (Abecma) vs 5% with standard regimens.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Mammogram Advice Varies for Older, Breastfeeding Moms Mammogram Advice Varies for Older, Breastfeeding Moms
Older, Breastfeeding Mothers Face Differing Advice About MammogramsMDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2024 Category: Cancer & Oncology Tags: Ob/Gyn & Women ' s Health Source Type: news
